Stock Notes

Alembic Pharmaceuticals

Every Finvezto stock note on Alembic Pharmaceuticals, dated and newest first. Coverage spans pharma.

2 notes and counting
28 Jul 2026
Alembic Pharmaceuticals received United States FDA final approval for prucalopride tablets in 1 milligram and 2 milligram strengths.
The drug is the generic of Takeda's Motegrity for chronic idiopathic constipation, adding a long-course gut motility treatment to its United States book.
19 Jun 2026
Alembic Pharmaceuticals won USFDA tentative approval for its binimetinib tablet, a drug with US sales of about 260 million dollars.
Tentative approval confirms the filing's quality while final clearance waits on the innovator's patent and exclusivity expiry.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.